



Press release

Invitation to presentation of BioArctic's Interim Report for the period January - March 2021 on April 21 at 9.30 a.m. CET

Stockholm, Sweden, April 15, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's Interim Report for the period January – March 2021 on Wednesday, April 21, 2021, at 08:00 a.m. CET.

In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on April 21, at 09:30 CET, where Gunilla Osswald, CEO, and Jan Mattsson, CFO, will present BioArctic and comment on the Interim Report for the period January – March 2021, followed by a Q&A-session.

To attend, please dial-in at one of the numbers below, from:

Sweden: +46 8 505 583 51

Denmark: +45 781 501 08

Germany: +49 692 222 203 77

The Netherlands: +31 107 129 162

Norway: +47 239 639 38

Switzerland: +41 225 675 632

UK: + 44 333 300 9032

US: + 1 833 249 8405

Webcast: <https://tv.streamfabriken.com/bioarctic-q1-2021>

The webcast will also be available on demand on BioArctic's corporate website <https://www.bioarctic.se/en/section/investors/presentations/> after the presentation.

For more information, please contact:

Oskar Bosson, VP Communications and Investor Relations, BioArctic AB

E-mail: oskar.bosson@bioarctic.se

Tel: + 46 704 10 71 80

This information was submitted for publication at 08:00 a.m. CET on April 15, 2021.

**About BioArctic AB**

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and outlicensing potential. BioArctic's Class B share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.